The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
By combining in vivo and in vitro proximity ligation technologies, highly accurate and contiguous genomes can help accelerate more traditional, genetic-marker based crop breeding.
Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
Reinstating the CRISPR patent interference with the Broad Institute would allow UC to argue that Jennifer Doudna and Emmanuelle Charpentier invented it first.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
The program will provide two young scientists with funding for independent research as well as resources to help them commercialize their technology.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.